Researchers find safety disclaimers do not register with consumers

The study indicates patients discount wording that indicates the FDA has not approved supplement claims.

Safety advocate, DOJ settle kickback allegations

The agreement includes a $1-million payment.

IPG merges ICC Lowe shops into FCB Health, amid sluggish digital growth

IPG merges ICC Lowe shops into FCB Health, amid sluggish digital growth

Holding company will now focus on two health networks—FCB Health and McCann Health

Five things for pharma marketers to know: Tuesday March 3

Five things for pharma marketers to know: Tuesday March 3

NICE greenlights Harvoni for Britain's national formulary, Pacira received a CRL instead of an expanded indication and Novo's latest diabetes outreach focuses on patients instead of drug brands.

Amgen results for Kyprolis could sideline Velcade

Amgen results for Kyprolis could sideline Velcade

Analysts say head-to-head study results could make Kyprolis the lead treatment.

Oncologist's petition is latest salvo, as drug-pricing issue rises to new prominence

Oncologist's petition is latest salvo, as drug-pricing issue rises to new prominence

Drugmakers face increasing pressure on pricing from insurers and PBMs.

Pradaxa antidote goes to FDA

The breakthrough designation therapy drug was the first for its drug class.

GAO: Dementia patients receiving harmful antipsychotics

Researchers said 33% of Medicare Part D nursing home patients were receiving the drug for symptoms associated with dementia.

Five things for pharma marketers to know: Monday, March 2

Five things for pharma marketers to know: Monday, March 2

Boston Scientific buys Endo men's health business; Ranbaxy generic Nexium and Valcyte approvals denied by courts; BMS receives priority review for Opdivo lung-cancer indication.

Five things for pharma marketers to know: Friday, February 27

Five things for pharma marketers to know: Friday, February 27

Novartis heart failure drug's trial changed due to Alzheimer's disease concerns; Gilead appears to be stashing profits overseas; BMS releases high cure rate data for its investigational HCV combination.

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.

Email Newsletters